|1.||Son, Miwon: 6 articles (01/2015 - 10/2008)|
|2.||Lee, Tae Ho: 3 articles (07/2014 - 10/2008)|
|3.||Choi, Myung-Gyu: 2 articles (07/2015 - 07/2013)|
|4.||Lee, Oh Young: 2 articles (07/2015 - 03/2014)|
|5.||Rhee, Poong-Lyul: 2 articles (07/2015 - 07/2014)|
|6.||Kwon, Yong Sam: 2 articles (01/2015 - 05/2013)|
|7.||Lee, Kwang Jae: 1 article (07/2015)|
|8.||Lee, Joon Seong: 1 article (07/2015)|
|9.||Sung, In Kyung: 1 article (07/2015)|
|10.||Choi, Suck Chei: 1 article (07/2015)|
10/01/2008 - "To develop a therapeutic for functional dyspepsia (FD), a prokinetic agent, DA-9701 has been newly formulated with Pharbitis Semen and Corydalis Tuber and we evaluated the gastroprokinetic effects of DA-9701 in comparison with conventional prokinetics. "
03/01/2015 - "DA-9701, a new prokinetic agent for the treatment of functional dyspepsia, is formulated with Pharbitis semen and Corydalis tuber. "
07/21/2013 - "Our findings suggest that DA-9701 has therapeutic potential for the treatment of functional dyspepsia."
05/30/2013 - "DA-9701, a compound consisting of a combination of Corydalis Tuber and Pharbitidis Semen, has being developed for treatment of functional dyspepsia. "
01/01/2012 - "DA-9701 is a new botanical drug composed of the extracts of Corydalis tuber and Pharbitidis semen, and it is used as an oral therapy for the treatment of functional dyspepsia in Korea. "
07/31/2014 - "Although NDI-K symptom scores and quality of life scores were improved after 4 weeks of treatment compared with baseline values in patients with minimal change esophagitis, DA-9701 did not improve the symptom scores or quality of life scores compared with the placebo."
07/31/2014 - "We assessed the efficacy of DA-9701 in symptomatic patients with minimal change esophagitis. "
07/31/2014 - "Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study."
07/31/2014 - "Patients with minimal change esophagitis presenting with reflux or dyspeptic symptoms were randomly assigned to receive either DA-9701 30 mg or placebo t.i.d. "
07/01/2014 - "The aim of this study was to evaluate the effect of DA-9701 on colorectal distension (CRD)-induced visceral hypersensitivity in a rat model. "
07/01/2014 - "The administration of DA-9701 resulted in a significant increase in pain threshold in rats with CRD-induced visceral hypersensitivity."
07/01/2014 - "Effect of DA-9701 on colorectal distension-induced visceral hypersensitivity in a rat model."
05/30/2013 - "DA-9701 also showed an analgesic effect in rats with colorectal distension induced visceral hypersensitivity and an antinociceptive effect in beagle dogs with gastric distension-induced nociception. "
|4.||Parkinson Disease (Parkinson's Disease)